Jun 19, 2017
Mycenax To Attend BIO 2017 In San Diego
The BIO International Convention (BIO 2017), will take place on June 19-22 2017 in San Diego, CA, United States. Mycenax’s business development team will be attending this event to meet partnering opportunities associated with our pipelines, including TuNEX® and LusiNEX.
The BIO International Convention is the largest annually held global event for the biotechnology industry. The event features keynotes and sessions from policymakers, scientists and celebrities. It will be organised by the Biotechnology Industry Organisation (BIO).
TuNEX®, a soluble tumor necrosis receptor (TNFR) fusion protein, is a biobetter version of Enbrel® sold by Amgen and Pfizer. TuNEX® can be used for the treatment of inflammatory symptoms by rheumatoid arthritis (RA). Phase III clinical study of TuNEX® for RA was completed, and NDA will be soon obtained in Taiwan. In addition to RA, phase III study of another indication ankylosing spondylitis will start in Taiwan.
LusiNEX is Mycenax’s tocilizumab, a biosimilar version of Actemra®, is the humanized monoclonal antibody IgG1 targeting interleukin-6 receptor (IL-6R). By binding IL-6R, it blocks the inflammatory response and joint erosion. LusiNEX is under process development now, and CTA/IND submission in Europe and Taiwan are expected in 2017.
To meet with Mycenax representative in advance of the BIO Convention, or to learn more about our pipelines and other services, get in touch using our contact form or email us at info@mycenax.com.tw.
Source：Mycenax Biotech Inc.
http://www.mycenax.com.tw/en/news.php?act=view&no=23
The BIO International Convention is the largest annually held global event for the biotechnology industry. The event features keynotes and sessions from policymakers, scientists and celebrities. It will be organised by the Biotechnology Industry Organisation (BIO).
TuNEX®, a soluble tumor necrosis receptor (TNFR) fusion protein, is a biobetter version of Enbrel® sold by Amgen and Pfizer. TuNEX® can be used for the treatment of inflammatory symptoms by rheumatoid arthritis (RA). Phase III clinical study of TuNEX® for RA was completed, and NDA will be soon obtained in Taiwan. In addition to RA, phase III study of another indication ankylosing spondylitis will start in Taiwan.
LusiNEX is Mycenax’s tocilizumab, a biosimilar version of Actemra®, is the humanized monoclonal antibody IgG1 targeting interleukin-6 receptor (IL-6R). By binding IL-6R, it blocks the inflammatory response and joint erosion. LusiNEX is under process development now, and CTA/IND submission in Europe and Taiwan are expected in 2017.
To meet with Mycenax representative in advance of the BIO Convention, or to learn more about our pipelines and other services, get in touch using our contact form or email us at info@mycenax.com.tw.
Source：Mycenax Biotech Inc.
http://www.mycenax.com.tw/en/news.php?act=view&no=23